Tanzania Depression Therapeutics Market Report 2022 to 2030

Tanzania Depression Therapeutics Market Analysis

$ 3999

Tanzania's depression therapeutics market is expected to grow from $4 Mn in 2022 to $6 Mn in 2030 with a CAGR of 6.1% for the forecasted year 2022-2030. The growing demand for effective depression treatments and the rising government initiatives to promote awareness about depression in Tanzania are responsible for the expansion of the market. The Tanzania depression therapeutics market is segmented by drug type, therapies, indication, and end users. Tanga Pharmaceuticals, Afya Bora Pharma, and AbbVie are the major players in the Tanzania depression therapeutics market.

ID: IN10TZPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Dr. Parul Choudhary

Buy Now

Tanzania Depression Therapeutics Market Executive Analysis

Tanzania's depression therapeutics market size is at around $4 Mn in 2022 and is projected to reach $6 Mn in 2030, exhibiting a CAGR of 6.1% during the forecast period. Tanzania is moving toward universal healthcare; in 2020-21, the government allotted $387.9 Mn for the health sector, $155.5 Mn of which will be spent on development projects to assist the government in implementing its health-improving initiatives. In 2022-23, the sector will be allotted $0.47 Bn. International donors supplement healthcare funding by contributing up to 40% of the health budget. The US government contributes significantly to Tanzanian government assistance initiatives through USAID and the CDC. Health insurance coverage remains poor, with only 32% of Tanzanians having health insurance as of 2019. Only 1% of those people have private health insurance.

In Tanzania, the point prevalence of depression was linked with lower self-reported physical health status and a large treatment gap. Depression had a crude and corrected prevalence rate of 21.2. Antidepressants are used to treat mood disorders such as anxiety and depression, as well as pain and sleeping problems. The most commonly prescribed form of antidepressant is selective serotonin reuptake inhibitor (SSRI), which includes Sertraline, Fluoxetine, and Citalopram. Serotonin and norepinephrine reuptake inhibitors (SNRIs) are comparable to SSRIs. Venlafaxine and duloxetine are two examples. Bupropion functions differently than SSRIs and SNRIs. It also helps individuals quit smoking and treats seasonal affective disorder. Tricyclics, tetracyclic, and monoamine oxidase inhibitors (MAOIs) are examples of older antidepressant drugs. Because they cause more side effects than other medications, they are given less frequently. They are, however, more effective for some individuals.

Tanzania Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Depression is a prevalent mental health illness in Tanzania, with prevalence rates increasing in recent years. As a result, there is a larger demand for effective depression treatments, which is anticipated to drive market development. In Tanzania, there is increasing consciousness and acceptance of mental health problems, which has aided to reduce the stigma associated with depression. This may lead to a rise in the number of people seeking therapy for depression and an increase in the demand for depression therapeutics. Tanzania's government has made measures to address mental health matters, such as developing a mental health policy and opening mental health clinics. These initiatives have the potential to expand access to depression treatments while also driving the Tanzania depression therapeutics market development.

Market Restraints

Tanzania is a low-income country with poor healthcare access, especially in rural areas. This may make it difficult for people suffering from depression to acquire effective treatment, restraining market development. Depression medicines can be expensive, making them unaffordable for many Tanzanians. This could stifle market growth. Tanzania has restricted public capital for mental health services, which may limit the availability of depression treatments and slow the Tanzania depression therapeutics market growth.

Competitive Landscape

Key Players

Salama Pharmaceuticals (TZA)
Shelys Pharmaceutical (TZA)
Zenufa Laboratories (TZA)
Tanga Pharmaceuticals (TZA)
Afya Bora Pharma (TZA)
AbbVie
AstraZeneca
Bristol-Myers Squibb
Cipla
Eli Lily
GlaxoSmithKline
Johnson & Johnson

Healthcare Policies and Regulatory Landscape

The National Health Insurance Fund (NHIF) is a Social Health Insurance Institution created under the National Health Insurance Act, Cap 395, with the primary goal of ensuring that people have access to healthcare services. It is a government agency that reports to the Ministry of Health, Community Development, Gender, the Elderly, and Children (MHCDGEC). Despite the compulsory enrollment arrangement for public servants, the Fund's coverage has expanded to include Councilors, private companies, educational institutions, private individuals, children under the age of 18, farmers in cooperatives, and organized registered groups such as Machinga and Bodaboda groups. The Bunge Health Insurance Scheme, which serves members of the Zanzibar House of Representatives, is also administered by the Fund. The Fund covers the costs of medicines given in generic names, as well as medical consumables, according to the National Essential Medicines List (NEMLIT) and an extra medicine list suggested (to NHIF) by experts and stakeholders. In Tanzania, there are no particular reimbursement policies in effect for depression therapeutics. The NHIF usually reimburses healthcare providers for services rendered to patients, but the amount of reimbursement varies based on the service and provider.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

Antidepressants
Anxiolytics
Anticonvulsants
Noradrenergic Agents
Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Psychotherapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation (TMS)
Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others

By End Users (Revenue, USD Billion):

NGOs
Asylums
Hospitals
Mental Healthcare Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Tanga Pharmaceuticals, Afya Bora Pharma, and AbbVie are the major players in the Tanzania depression therapeutics market.

The Tanzania depression therapeutics market is expected to grow from $4 Mn in 2022 to $6 Mn in 2030 with a CAGR of 6.1% for the forecasted year 2022-2030.

The Tanzania depression therapeutics market is segmented by drug type, therapies, indication, and by end users.